|By Marketwired .||
|May 28, 2014 07:30 AM EDT||
BOSTON, MA -- (Marketwired) -- 05/28/14 -- Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that J. Michael French, President and CEO, will present at the LD Micro Invitational 2014 on Wednesday, June 4th, 2014 at the Luxe Sunset Boulevard Hotel in Los Angeles.
The Company's presentation is scheduled to begin at 5:30 PM PST and will be available via a live webcast. To access the webcast, please go to http://wsw.com/webcast/ldmicro6/mrna.
There will be an opportunity for investors to meet one-on-one with management. Interested investors should contact Mr. Chris Lahiji, President, LD Micro at [email protected] for conference details and admission. To learn more about LD Micro and the LD Micro Invitational, please visit www.ldmicro.com.
About Marina Biotech, Inc.
Marina Biotech is an oligonucleotide therapeutics company with broad drug discovery technologies providing the ability to develop proprietary single and double-stranded nucleic acid therapeutics including siRNAs, microRNA mimics, antagomirs, and antisense compounds, including messengerRNA therapeutics. These technologies were built via a roll-up strategy to discover and develop different types of nucleic acid therapeutics in order to modulate (up or down) a specific protein(s) which is either being produced too much or too little thereby causing a particular disease. We believe that the Marina Biotech technologies have unique strengths as a drug discovery engine for the development of nucleic acid-based therapeutics for rare and orphan diseases. Further, we believe Marina Biotech is the only company in the sector that has a delivery technology in human clinical trials with differentiated classes of payloads, through licensees ProNAi Therapeutics and Mirna Therapeutics, delivering single-stranded and double-stranded nucleic acid payloads, respectively. Our novel chemistries and other delivery technologies have been validated through license agreements with Roche, Novartis, Monsanto, and Tekmira. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and a preclinical program in myotonic dystrophy. Marina Biotech's goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at www.marinabio.com.
Marina Biotech Forward-Looking Statements
Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to obtain additional funding; (ii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (v) the ability of Marina Biotech and/or a partner to develop and commercialize products prior to, and that can compete favorably with those of, competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent filings with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update or supplement forward-looking statements because of subsequent events.
J. Michael French
President and CEO
Marina Biotech, Inc.
Jul. 5, 2015 10:15 AM EDT Reads: 1,213
Jul. 5, 2015 10:00 AM EDT Reads: 2,762
Jul. 5, 2015 10:00 AM EDT Reads: 1,190
Jul. 5, 2015 09:45 AM EDT Reads: 1,612
Jul. 5, 2015 09:30 AM EDT Reads: 1,575
Jul. 5, 2015 09:30 AM EDT Reads: 1,229
Jul. 5, 2015 09:15 AM EDT Reads: 1,176
Jul. 5, 2015 09:00 AM EDT Reads: 2,378
Jul. 5, 2015 09:00 AM EDT Reads: 1,175
Jul. 5, 2015 09:00 AM EDT Reads: 1,454
Jul. 5, 2015 08:45 AM EDT Reads: 1,446
Jul. 5, 2015 08:00 AM EDT Reads: 1,186
Jul. 5, 2015 07:45 AM EDT Reads: 1,260
Jul. 5, 2015 06:45 AM EDT Reads: 1,357
Jul. 5, 2015 04:00 AM EDT Reads: 2,046